RXI Pharmaceuticals (RXII) Stock Chart Analysis Video

RXI Pharmaceuticals Stock Chart Analysis Video

Even though RXI Pharmaceuticals Corp. (OTCBB: RXII) has only been trading for less than two months, the technicals show that a base has formed and that there is potential for a move in the near term as the moving averages have converged and the bollinger bands are tightening. Technical traders will be watching for an increase in volume to hold support at 8 cents and for pressure to try and take out resistance at 9 cents.

RXi Pharmaceuticals is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, next-generation RNAi platform. Therapeutics that use RNA interference, or “RNAi,” have great promise because of their ability to “silence,” or down-regulate, the expression of a specific gene that may be overexpressed in a disease condition. Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, RXi’s first RNAi product candidate, RXI-109, which targets CTGF (connective tissue growth factor), will commence human clinical trials in anti-scarring in 2012.

RXI Pharmaceuticals (RXII) Stock Quote and News:

Disclaimer: Neither http://www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has received no compensation for this article from and owns no shares of the aforementioned company(ies). Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/about-2/disclaimer.

0 comments

Add your comment

Commenting is allowed only for registered users.

Other articlesgo to homepage

	Ecosphere Delivers Two More Ozonix Water Treatment Units to Hydrozonix(0) Ecosphere Technologies, Inc. (OTCBB: ESPH) said Monday that it delivered two more Ozonix EF80 units to Hydrozonix LLC as part of a long-term contract with water treatment solutions company. Hydrozonix is a strategic alliance of a consortium of the principals at Phillips and Jordan, Inc., the Siboney Group and PBA Holdings that provides mobile, eco-friendly

	Glaxo Genital Herpes Vaccine Flops but Genocea a Buy in Vaccine Space(0) By Rex Graham A Glaxo Smith Kline (GSK) genital herpes vaccine recently flopped in a large clinical trial, but “next generation” genital herpes vaccines by Genocea Biosciences, Agenus, Inc. (AGEN), Vical, Inc. (VICL), and Sanofi Pasteur (SNY) offer new hope for an effective vaccine treatment. A Yale University study published in the Nov. 15, 2012,

	Senate Approves Tax Hikes and Delay in Spending Cuts(0) Technically, the United States has gone over the fiscal cliff with January 1 arriving before a new budget was passed to avert a series of automatic tax increases and deep spending cuts. But, the Senate said Tuesday morning that the White House and Senate Republicans have come to terms to raise taxes on households bringing-in

	ALR Technologies Names Former Pfizer Exec as Chief Commercial Officer(0) Health information company ALR Technologies, Inc. (OTCBB: ALRT) on Monday disclosed the appointment of William S. Smith as Chief Commercial Officer and member of the Board of Directors, effective January 1, 2013. Smith will oversee sales and marketing, investor relations, public affairs, communications and government affairs, according to a corporate statement. Previously, Smith spent ten

	Cellceutix Enters $10 Million Share Purchase Agreement, Shares Jump(0) Cellceutix Enters Into a $10 Million Common Stock Purchase Agreement With Aspire Capital Fund, LLC Cellceutix Corporation (OTCBB: CTIX) (the “Company”), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, today announced that it has entered into a common stock purchase agreement

Stay Informed

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

RXI Pharmaceuticals Stock Chart Analysis Video

RXI Pharmaceuticals (RXII) Stock Quote and News:

0 comments

Add your comment

Other articlesgo to homepage

Ecosphere Delivers Two More Ozonix Water Treatment Units to Hydrozonix(0)

Glaxo Genital Herpes Vaccine Flops but Genocea a Buy in Vaccine Space(0)

Senate Approves Tax Hikes and Delay in Spending Cuts(0)

ALR Technologies Names Former Pfizer Exec as Chief Commercial Officer(0)

Cellceutix Enters $10 Million Share Purchase Agreement, Shares Jump(0)

OTCBB News

Stay Informed

Dana-Farber to Host Cellceutix Trials

Diabetes Rate Growing Exponentially

Gateways

Contacts and information

Social networks

Most popular categories